In the present study, we have analysed the effects of transforming growth factor-beta (TGF-b) signaling on the growth behavior of pancreatic carcinoma cells in vitro and on their tumorigenicity in vivo. Ectopic expression of dominant-negative mutants of the TGF-b type II receptor or type I receptor/activin receptor-like kinase 5 (ALK5) in TGF-b-sensitive pancreatic ductal adenocarcinoma PANC-1 cells prevented the TGF-b-induced activation of transfected Smad-responsive reporter genes and growth arrest. The growth-inhibitory effect was mimicked by stable expression of kinase-active ALK5 (ALK5-T204D), and was dependent on ALK5's ability to activate Smad signaling, as a ALK5-derived mutant with an intact kinase domain but deficient in its ability to activate Smads (RImL45) failed to suppress proliferation in the absence of added TGF-b. Moreover, this mutant often displayed opposite effects to those of ALK5-TD and blocked various ligand-induced responses in vitro, indicating that it acts in a dominant-negative fashion to inhibit endogenous wild-type receptors. ALK5-TD-, but not RImL45-TDtransduced cells underwent epithelial-to-mesenchymal transition, exhibited a higher ratio of thrombospondin-1 to vascular endothelial growth factor-A expression and upregulated various metastasis-associated genes. Upon orthotopic transplantation of PANC-1 clones into immunodeficient mice, ALK5-TD, but not RImL45-TD, greatly reduced tumor size and induced the formation of liver metastases in otherwise non-metastatic PANC-1 cells. These results suggest a causal, dominant role for the endogenous Smad2/3 signaling pathway in the tumor suppressor and prometastatic activities of TGF-b in pancreatic tumor cells.
Introduction
Transforming growth factor-beta (TGF-b) belongs to a large superfamily of pleiotropic cytokines that regulate complex physiological processes such as cell proliferation, differentiation, matrix production, cell motility and apoptosis (Massague´, 1998; Moustakas et al., 2002) . Dysregulation of TGF-b signaling contributes to several pathological processes including fibrosis, autoimmune diseases and cancer (Massague´et al., 2000) . The TGF-bs elicit their biological effects by binding to type II and type I transmembrane receptor serine-threonine kinases, TbRII and TbRI/activin receptor-like kinase 5 (ALK5) (Franze´n et al., 1993) . Ligand-activated ALK5 phosphorylates receptor-regulated Smads, Smad2 and 3, which form a heteromeric complex with the common mediator Smad4 (also termed DPC4) and this complex translocates to the nucleus where it regulates gene transcription. This process is antagonized by the inhibitory Smad7, itself a Smad-regulated gene, which downregulates TGF-b signaling by binding to activated ALK5 and interfering with its ability to phosphorylate Smad2/3 (Derynck and Zhang, 2003) .
TGF-b can behave as both a tumor suppressor and a tumor promoter. Its tumor suppressor function can be explained largely by its ability to inhibit proliferation of epithelial and lymphoid cells (from which most human cancers originate) and to induce apoptosis (Derynck et al., 2001) . However, late-stage human carcinomas often become resistant to TGF-b growth inhibition, and in addition, secrete elevated levels of this growth factor (Reiss and Barcellos-Hoff, 1997; Derynck et al., 2001) . At this point, TGF-b's role switches to that of a tumor promoter by enhancing epithelial-to-mesenchymal transition (EMT), a process during which the epithelial phenotype is lost, and a mesenchymal phenotype is acquired and which is associated with enhanced invasiveness and metastasis (reviewed by Zavadil and Bo¨ttinger (2005) ). Genetic manipulation of the TGF-b pathway in an experimental animal model of carcinogen-induced mammary tumorigenesis (Bo¨ttinger et al., 1997) and in metastatic mammary tumor cell lines (Muraoka-Cook et al., 2005a) validated the tumor suppressive and metastasis-promoting function of TGF-b in late-stage cancer progression.
Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease in which non-surgical therapy is ineffective and in which the majority of patients harbor metastatic lesions at presentation, precluding the possibility for curative surgical intervention (Warshaw and Fernandez-del Castillo, 1992) . These cancers frequently overexpress all three TGF-b isoforms (Friess et al., 1993b) . The role of TGF-b signaling as a tumor suppressor pathway in pancreatic carcinoma is best illustrated by the presence of chromosomal deletions and mutations in DPC4 in 55% of pancreatic tumors (Hahn et al., 1996) , a tumor suppressor that has been implicated in mediating the growth inhibitory (Peng et al., 2002) and antiangiogenic (Schwarte-Waldhoff et al., 2000) effects of TGF-b. Fifty percent show an overexpression of the inhibitory Smad7 (Kleeff et al., 1999) ; moreover, in vivo disruption of TGF-b signaling by Smad7 leads to premalignant ductal lesions in the pancreas (Kuang et al., 2006) . Inactivating mutations in both TGFBR1 (Goggins et al., 1998) and TGFBR2 have been observed in pancreatic carcinoma, but are less common than downregulation of ALK5 combined with elevated expression of TbRII (Friess et al., 1993a; Baldwin et al., 1996) . The high prevalence of loss-offunction mutations in Smad4 or other disturbances in Smad signaling (Nicolas and Hill, 2003 ; reviewed by Derynck et al. (2001) ) may similarly result in loss of tumor suppression, eventually resulting in the resistance of tumors towards the antiproliferative effect of this growth factor which in PDAC is mediated primarily via the cyclin-dependent kinase (cdk) inhibitor p21 WAF1/CIP1 (Voss et al., 1999) . Consequently, pancreatic cancer cellderived TGF-bs cannot act to suppress the growth of the cancer cells, but may promote invasion and metastasis. This process can be further enhanced by activated oncogenes, such as ras, which is known to cooperate with TGF-b signaling in EMT and cellular invasion (Janda et al., 2002; Oft et al., 2002) . Indeed, pancreatic tumor cells genetically engineered to express a soluble TbRII showed a marked decrease in expression of metastasis-associated genes and reduced metastasis in vivo (Rowland-Goldsmith et al., 2002) .
Although Smads are well-characterized TGF-b signal transducers, TGF-b also signals through several Smadindependent pathways eventually resulting in complex cross-talk between the Smad and non-Smad, for example, mitogen-activated protein kinase (MAPK) signaling pathways (Derynck and Zhang, 2003; Javelaud and Mauviel, 2005) . A central issue therefore relates to the contribution of Smad signaling to tumor suppression and the prometastatic function of TGF-b and how changes in the balance between TGF-b receptordependent Smad2/3 signaling and MAPK signaling affect tumor suppression. Observations that were derived mainly from breast cancer cellular models showed that signaling through the Smad2/3 pathway could mediate tumor suppressor and prometastatic effects of TGF-b on these cells, depending on the stage of progression of the cells and other cooperating contextual changes (Tian et al., 2004; Deckers et al., 2006 ; reviewed by Kang (2006) ). However, equivalent studies at the level of the TGF-b receptors have not been performed in PDAC. We have therefore addressed this issue using a PDAC cell line (PANC-1) that has retained a functional TGF-b/Smad pathway (Chen et al., 2002; Fensterer et al., 2004) and is thus representative of an early stage of pancreatic tumorigenesis. By engineering these cells to express various ALK5 mutants (kinasedefective, Smad activation-incompetent), we present evidence from in vitro and in vivo experiments that both the tumor suppressor function and the prometastatic effects of ALK5 depend on its Smad activating function. This study for the first time presents a comprehensive functional analysis of the role of ALK5 in the growth inhibitory and prometastatic responses of pancreatic carcinoma cells to TGF-b1 in vitro and in vivo.
Results
TbRII function and the ALK5 kinase activity are required for TGF-b/Smad-mediated transcription and growth inhibition PANC-1 cells are known to respond to TGF-b with growth inhibition (Giehl et al., 2000; Chen et al., 2002) . To establish whether the antiproliferative response to this growth factor is TbRII-dependent, we employed PANC-1 cells retrovirally transduced in a stable fashion with dominant-negative TbRII (D404G). These cells have been demonstrated previously to be refractory to TGF-b-induced stimulation of reporter gene (3TP-lux) activity and matrix gene expression (Ungefroren et al., 2005) . Importantly, TbRII-DG-transduced PANC-1 cells were unable to respond to this growth factor with growth inhibition as were MiaPaCa2 cells, known to harbor a loss-of-function mutation in TbRII (Freeman et al., 1995) (Figure 1a) .
In order to examine the role of ALK5 for Smadmediated transcriptional responses, particularly TGF-bmediated growth suppression, in this cell line, we initially used transient transfection of kinase-deficient (kd) ALK5 (K232R) to block the function of endogenous ALK5. This mutant effectively suppressed both TGF-b/Smad-mediated transcription of the Smad3-responsive reporter p6SBE-luc (Dai et al., 1998) and of the Smad-responsive Smad7 promoter (Figure 1b ). For analysis of the antiproliferative response, we employed PANC-1 cells stably expressing ALK5-KR from a retroviral vector. These cells, too, have been characterized in a previous publication and shown to be insensitive to TGF-b-induced Smad activation and biglycan induction (Ungefroren et al., 2005) . Notably, TGF-b-induced growth inhibition, as measured by DNA synthesis, was relieved in these cells compared with vector-transduced and parental controls ( Figure 1c ) and this was associated with a failure to upregulate expression of p21 WAF1 (data not shown). These results clearly show that ALK5, via its kinase activity, mediates Smad-dependent transcriptional responses, such as TGF-b-induced growth arrest, in pancreatic carcinoma cells.
Effects of stable expression of ALK5-TD and its Smadbinding defective mutant (RImL45-TD) on basal and TGF-b-induced Smad activation To look at the effects of altering type I receptor expression on TGF-b signaling pathways in PANC-1 cells and to explore in more detail the contribution of the Smad pathway for TGF-b-induced growth inhibition, neoangiogenesis and metastasis, cells were retrovirally transduced to create clones that stably express ALK5 or its Smad-binding defective mutant RImL45 (Yu et al., 2002) . In this mutant, replacement of three L45 loop residues (N265, D267 and N268) with alanine abolishes the ability of the receptor to interact with and phosphorylate its Smad substrates without affecting its kinase activity or its ability to activate other signaling pathways such as the extracellular signal-regulated kinase (ERK) pathway (Yu et al., 2002) . In order to avoid activation of the endogenous receptors, we utilized the kinase active mutants ALK5-T204D (ALK5-TD) and (rat) RImL45-T202D (RImL45-TD) (Wieser et al., 1995) . Following geneticin selection and isolation, several individual clones were obtained, which displayed considerable and approximately equal expression of the mutant proteins, which were at least fourfold higher than the level of endogenous ALK5 ( Figure 2a) . Next, we verified the ability of these mutant receptor constructs to activate the Smad pathway. Basal levels of Smad2 phosphorylation were higher in ALK5-TD-expressing cells than in RImL45-TD-transduced counterparts and in the latter were not different from controls ( Figure 2a) . Similarly, amounts of activated Smad3 were hardly detectable in RImL45-TD-transduced cells (Figure 2b , lanes 3-4) and in unstimulated parental cells (Figure 2b , lane 5). However, the amount of both phospho-and total Smad3 in ALK5-TDexpressing cells appeared to be low (Figure 2b To determine the consequences of RImL45-TD expression for ligand-induced activation of endogenous ALK5, we assessed the levels of phosphorylated Smad2 in four different PANC-1-RImL45-TD clones after TGF-b stimulation. Notably, expression of RImL45-TD efficiently interfered with activation of Smad2 with the strongest effect seen in the two clones with the highest transgene expression (no. 44 and no. 17, Figure 2c ). Smad4 expression levels showed no changes among the stably infected PANC-1 cell clones of different constructs with or without TGF-b1 ligand (data not shown). These data suggest that RImL45 acts in a dominant-negative manner to suppress Smad activation by endogenous wild-type receptors.
Effects of stable expression of ALK5-TD and its Smadbinding defective mutant on Smad-dependent transcriptional activity and various TGF-b response genes To determine whether manipulations of the type I receptor had the expected outcome on gene expression, we examined the response of Smad2/3-specific reporter genes to ALK5-TD and RImL45-TD in transient reporter gene assays. In a previous publication, we have demonstrated that ectopic expression of ALK5-TD, but not RImL45-TD, can mimic the TGF-b-induced activation of the p6SBE-Luc reporter in PANC-1 cells (Ungefroren et al., 2005) . To assess if ALK5-TD on its own can also transcriptionally repress the Myc gene (which is a prerequisite for induction of p21 WAF1 (Claassen and Hann, 2000) and is accomplished by TGF-b through binding of Smad3 to a repressive Smadbinding element in the Myc promoter (Frederick et al., 2004) , we performed transient co-transfection experiments with pMYC-TA-Luc along with ALK5-TD or RImL45-TD. ALK5-TD suppressed activity from the Myc promoter, whereas RImL45-TD blunted the inhibitory effect of exogenous TGF-b, again suggesting dominant-negative interference with endogenous Smad signaling ( Figure 3a ). Kinase-active ALK5, but not its Smad-binding defective counterpart, also potently induced reporter gene activity from the Smad7 promoter in the absence of added TGF-b (Figure 3a (Derynck and Zhang, 2003) . Notably, p-ERK1/2 levels were increased in RImL45-TD expressing cells relative to vector controls ( Figure 3b ), suggesting either direct activation of ERK by the RImL45 kinase domain or indirect activation through de-repression from Smad inhibition (see Discussion). These data confirm that various proliferation and cell-cycle-associated genes are altered by TGF-b/ALK5 in their transcriptional activity and that these effects are faithfully mimicked by ALK5, but not the Smad binding-deficient RImL45.
Expression of ALK5-TD, but not RImL45-TD, mimicked the growth inhibitory effects of TGF-b in PANC-1 cells Above we have shown (Figure 1 ) that ALK5 is responsible for mediating the growth inhibitory effect of TGF-b in PANC-1 cells and that ALK5-TD, but not RImL45-TD, can mimic the underlying molecular changes, such as induction of p21
WAF1
. To investigate whether ectopic expression of these mutants affects the growth behavior of PANC-1 cells (in the absence of exogenous ligand) under standard culture conditions (in medium with 10% fetal calf serum), we measured proliferation by cell counting, mitochondrial activity and cell-cycle profiling using flow cytometry analysis. The cell number increased much more rapidly during a 3-day period in parental and Smad binding-deficient mutant-bearing cells compared with ALK5-TD-transduced cells (Figure 4a ). Similar results were obtained in the EZ4U assay, which assesses mitochondrial activity based on changes in ATP consumption (Figure 4b) . However, the two clones expressing the highest RImL45-TD levels (no. 17 and no. 44) proliferated more rapidly than the parental cells (Figure 4a and b) . As expected from the above results, ALK5-TD-expressing cells had a high percentage of cells in the G1 phase of the cell-cycle and a lower proportion of cells in S phase than vector and parental controls (Figure 4c ). RImL45-TD-transduced cells did not differ significantly from parental cells with respect to the G1 and S phase. Together, these data strongly support the assumption that, besides the kinase activity, the Smad-activating function of ALK5 accounts for most, if not all, of the antiproliferative effect. This is also reflected by the Smad-dependent regulation of various growth-controlling genes.
Expression of ALK5-TD mimicked the effect of TGF-b on genes involved in neoangiogenesis EMT, and invasion/ metastasis The Smad pathway has been shown to exert part of its tumor suppressive activity by inhibiting neo-angiogenesis (Schwarte-Waldhoff et al., 2000) . TGF-b positively regulates vascular endothelial growth factor (VEGF)-A, which is one of the most important proangiogenic factors, and thrombospondin-1 (TSP-1), which is a WAF1 and p27 KIP1 and for activation of ERK1/2 using a phospho-specific ERK antibody (p-ERK). Blots were reprobed with b-actin and total ERK2 (t-ERK2), respectively, to verify equal loading of total protein in each lane.
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B Schniewind et al potent inhibitor of tumor cell growth and angiogenesis (Lawler, 2000; Bornstein, 2001 ) and has been shown to oppose VEGF-A actions. Using quantitative real-timepolymerase chain reaction (PCR) we found the ratio of the relative expression levels of TSP-1 to VEGF-A in unstimulated control cells to approximate 1. In contrast, in ALK5-TD-expressing cells (clone no. 56 and pool) it was clearly >1, whereas in 4/4 of the RImL45-TDtransduced individual clones it was 51 (Figure 5a ). These data would suggest a preponderance of the antiangiogenic potential of the ALK5-TD-expressing cells.
Earlier studies have shown that PANC-1 cells respond to TGF-b treatment in vitro with EMT and a moderate increase in migratory and invasive behavior (Ellenrieder et al., 2001a) . However, the contribution of Smad signaling to this process remained controversial as Smad4 was recently reported to be dispensable for TGF-b-induced EMT in another pancreatic cancer cell line, COLO-357, and in HaCaT keratinocytes (Levy and Hill, 2005) . Notably, morphological signs of EMT with spindle-shaped cells and fibroblast morphology were observed only in ALK5-TD, but not in RImL45-TDexpressing PANC-1 cells (not shown). Both TGF-b1-stimulated parental PANC-1 cells and (unstimulated) PANC-1-ALK5-TD clones displayed a reduced expression of epithelial markers, such as E-cadherin ( Figure 5b ) and cytokeratin 18 (not shown), and a concomitant increase in mesenchymal markers N-cadherin and vimentin. Expression of the EMT-associated transcription factor Snail, which is a transcriptional repressor of E-cadherin (Peinado et al., 2004) , was elevated in ALK5-TD pools, albeit moderately, likely reflecting induction in some clones but not in others (Figure 5b ). Of note, the kinase-active RImL45 mutant was unable to induce these changes (Figure 5b ). TGF-b treatment of PANC-1 cells has been shown previously to result in strong upregulation of expression and activity of both matrix metalloproteinase-2 (MMP-2) and the urokinase plasminogen activator system and their inhibition caused significant reduction of TGF-b-induced invasiveness in these cells (Ellenrieder et al., 2001a) . Notably, expression of MMP-2 and plasminogen activator inhibitor-1 (PAI-1), another growth-and metastasis-associated gene overexpressed in PDAC (Rowland-Goldsmith et al., 2002) , was elevated in ALK5-TD-transduced PANC-1 cells (Figure 5c ). These results clearly show that ALK5-TD alone induces a gene expression profile characteristic for cells with a higher invasive potential. Figure 5a) . Interestingly, PANC-1-ALK5-TD showed a strong ability to form liver metastases (Figure 6d ). . No metastases were found at other body sites. These data are consistent with the crucial role of the Smad pathway for the tumor-suppressing and prometastatic activity of ALK5 and suggest that besides the antimitogenic activity, reduced neoangiogenesis accounts for the reduced size of tumors derived from kinase-active ALK5-expressing tumor cells. (Grau et al., 1997) . As MAPKs have been implicated in growth control by TGF-b, we also compared the effects of ALK5 mutants on ERK activation and found phospho-ERK1/2 levels to be increased in RImL45-TD-expressing cells. As this mutant still possesses an intact kinase domain, it might be capable of activating ERK directly (Yu et al., 2002) . Iglesias et al. (2000) have shown that Smad4 inhibits ras-dependent ERK signaling activity in ras-transformed keratinocytes. As in PANC-1 cells, which harbor a activating mutation (G12D) in one allele of the Ki-ras gene, TGF-b inhibited growth factormediated ERK activation in PANC-1 cells (Giehl et al., 2000) , the enhanced ERK activation in RImL45-TD expressing is likely the result of derepression. Interestingly, in two clones with high expression of RImL45-TD, this mutant enhanced the proliferation of pancreatic cells in the absence of added TGF-b, which could be a direct consequence of higher ERK activation. Alternatively, the growth-promoting effect may be the result of dominant-negative inhibition of endogenous wild-type receptors stimulated in an autocrine manner (see below).
Upon transplantation of the ALK5-transduced PANC-1 cells into the pancreas of immunodeficient mice, ALK5-TD-expressing cells formed tumors that were much smaller and had a lower proliferative index than tumors generated from RImL45-TD-expressing and parental cells. These results are in line with data showing that restoration of Smad4 to human pancreatic carcinoma cells suppressed tumor formation in vivo (Schwarte-Waldhoff et al., 2000; Duda et al., 2003) . Interestingly, RImL45-TD inhibited phosphorylation of Smad2 and repression of the Myc promoter in response to exogenous ligand and in some assays relieved the autoinhibitory effect of endogenously produced TGF-b (see above), together suggesting that this mutant acts in a dominant-negative fashion for Smad-mediated responses triggered by either exogenous or endogenous TGF-b. Such an effect has been observed in TGF-b regulation of the matrix proteoglycan biglycan in PANC-1 cells (Ungefroren et al., 2005) . A recent study by Tian et al. (2004) investigating the in vitro and the in vivo function of RImL45 in Ha-ras-transformed breast cancer cells found that this mutant, as in our model, selectively interfered with activation of endogenous Smad2 and Smad3 and enhanced the malignancy of xenografted tumors of the well-differentiated MIII cell line derived from MCF10A cells. We did not observe this tumor-promoting effect in vivo as tumors derived from RImL45-TD-expressing cells tended to be smaller than those from parental controls. The reason for this discrepancy between the in vitro and in vivo results is not known, but may be related to differences in the mutant construct (non-kinase-active vs kinase-active), the type of ras activated (Ha-ras vs Ki-ras), the site of xenograft growth (subcutaneous (s.c.) vs orthotopic) or to increased apoptosis in the RImL45-TD-bearing PANC-1 cells (see Figure 4c) .
Remarkably, we observed a significant reduction in vascular density in PANC-1-ALK5-TD as opposed to RImL45-TD and parental cell-derived tumors, which correlated with a higher ratio of antiangiogenic (TSP-1, PAI-I) to proangiogenic (VEGF-A) factor expression. This strongly suggests that Smad-mediated suppression of neoangiogenesis contributed to the antitumor effect and is in line with animal experiments showing that functional Smad4 expression blocks in vivo growth of pancreatic tumor cells by inhibiting neoangiogenesis, mechanistically occurring in part through upregulation of TSP-1 expression (Schwarte-Waldhoff et al., 2000) and/or downregulation of VEGF (Duda et al., 2003) . TGF-b is known to have both angiogenic and antiangiogenic properties consistent with its ability to induce VEGF-A and TSP-1. Recent studies from Smad knockout cells have shown that Smad2, but not Smad3, is critical for TSP-1 expression by TGF-b, whereas Smad3 has a key role in the stimulation of VEGF-A expression, thus implying an antiangiogenic function for Smad2 (Nakagawa et al., 2004) . The high ratio of TSP-1/VEGF-A in ALK5-TD vs RImL45-TD-expressing PANC-1 cells may thus be a direct consequence of elevated levels of activated Smad2 and concomitantly low levels of activated Smad3 (and decreased amounts TGF-b-dependent EMT has been shown to be a prerequisite for tumor progression and metastasis (Zavadil and Bo¨ttinger, 2005; Deckers et al., 2006 and references therein) . Notably, ALK5, but not RImL45, expression faithfully mimicked the phenotypic and molecular changes associated with EMT in PANC-1 cells. Our results add support to the contention that Smad signaling is required for TGF-b-induced EMT in pancreatic cancer cells and contradict observations in another TGF-b-sensitive, Smad4-positive pancreatic tumor cell line (Levy and Hill, 2005) . Our data are in agreement with the increased migratory activity and invasive behavior in vitro following stimulation of PANC-1 cells with TGF-b1 (Ellenrieder et al., 2001a, b) . Notably, following xenotransplantation of PANC-1 cells into mouse pancreas ALK5-TD strongly induced hepatic metastasis, while neither the Smadbinding-defective mutant (this study) nor a kinase-active mutant of the related ALK1, which signals through Smad1/5, was capable to do so (Ungefroren et al., 2007) . This suggests a crucial role for Smad2/3 in TGF-bdriven metastasis of pancreatic carcinoma cells to the liver and resembles the situation in MDA-MB-231 breast cancer cells where Smads are required for metastasis to bone (Kang et al., 2005; Deckers et al., 2006) . Also in the breast cancer model, Tian et al. (2004) noted that the prometastatic activity of TGF-b/ALK5 was inhibited when RImL45 was expressed in the more aggressive and metastatic MCF10CA1a (MIV) cell line. Unfortunately, a metastatic subline of PANC-1 was not available, precluding the test whether reduction in Smad2/3 signaling by expression of RImL45 would correlate with inhibition of the prometastatic activity.
In order to induce EMT, invasion and metastasis, ALK5-TD-induced Smad activation alone may not be sufficient, rather Smads must cooperate with non-Smad signaling cascades, for example, the Ras pathway (Oft et al., 1996 (Oft et al., , 2002 Janda et al., 2002) . PANC-1 cells have one mutated Ki-ras allele (Fensterer et al., 2004) and experiments inhibiting endogenous non-oncogenic ras activation by a dominant-negative ras mutant (H-ras (S17N)) suggested that ras activation by TGF-b1 is involved in TGF-b-induced EMT, invasion and metastasis, whereas cell-cycle-and proliferation-associated genes were not the primary targets of the interaction between the Ras and TGF-b cascades. A possible mechanism whereby Ki-ras drives metastasis may be promotion of nuclear accumulation of Smad2 previously phosphorylated by ALK5-TD, as has been suggested earlier for squamous carcinoma cells (Oft et al., 2002) . It is interesting to note that when expressed in normal mammary epithelial cells in vivo, ALK5-TD-expressing mice did not develop mammary tumors, whereas bigenic MMTV-ALK5-TD x-Neu mice developed tumors that were more metastatic than those derived from MMTVNeu mice, suggesting that mutant ALK5 kinase (enhanced TGF-b signaling) can provide epithelial cells with a 'gain-of-function' effect that synergizes with oncogene/ ras-induced transformation (Siegel et al., 2003; Muraoka-Cook et al., 2005b) . The underlying mechanism of prometastatic function of TGF-b/ALK5/Smad may, besides enhanced survival (Muraoka-Cook et al., 2005b) , affect homing of ALK5-TD-expressing cells to liver as has been suggested for metastases of Smad4-positive breast cancer cells to bone (Deckers et al., 2006; Kang, 2006) . More specifically, activated Smad signaling may induce factors through which the tumor cells communicate with the microenvironment of the metastasis site (Deckers et al., 2006) , a process which is needed for optimal tumor cell growth and metastasis.
Taken together, the results presented in this study establish the crucial role of the Smad activating function of ALK5 for both the antiproliferative response to TGF-b in vitro and the tumor suppressive and prometastatic functions of TGF-b in vivo in PDAC. Future studies should identify the gene targets of the Smad pathway by comparing the transcriptome from tumors induced by ALK5-TD versus those derived from RImL45-TD-expressing cells. Unravelling the molecular basis of this mechanism will deepen our understanding of the role of TGF-b in tumor progression and guide the development of new therapies for the management of pancreatic cancer aimed at selectively promoting the tumor suppressive activities of TGF-b/ALK5.
Materials and methods
Antibodies and reagents TGF-b1 was from R&D Systems (Wiesbaden, Germany) and was used at a concentration of 5 ng/ml. An antibody to ALK5 (V-22) was obtained from Santa Cruz Biotechnology (Heidelberg, Germany), to phospho-Smad2 from Cell Signaling Technology (Heidelberg, Germany), to Smad2 from Zymed (Berlin, Germany), to phospho-Smad3 from Biosource (Nivelles, Belgium), to Smad2/3, phospho-ERK1/2 (E-8) and ERK2 from Santa Cruz, to p21 WAF1 from BD Transduction Laboratories (Heidelberg, Germany), to p27 KIP1 (clone SX53G8) from DAKO (Glostrup, Denmark), to Dianova, Hamburg, Germany) , to CD31/PECAM-1 (clone MEC13.3, BD Pharmingen, Hamburg, Germany) and to b-actin from Sigma (Deisenhofen, Germany). All other reagents used were of analytical grade purity.
Cell lines and cell culture
Human pancreatic adenocarcinoma PANC-1, and MiaPaCa2 cells were maintained as described earlier (Chen et al., 2002) . PANC-1 cells stably transduced with various retroviral vectors were cultured in the presence of 700 mg/ml geneticin (active concentration, Invitrogen, Karlsruhe, Germany).
Construction of vectors, retroviral infection and clone selection
A cDNA for rat TbRImL45(T202D) (Yu et al., 2002) was excised from pRK5F and inserted into the retroviral vector TGF-b receptor type I in TGF-b-induced tumor suppression B Schniewind et al TJBA5bMoLink-neo (TJ-neo, Chen et al., 2002) . cDNA inserts of TbRII (D404G), kinase-active ALK5 (T204D) and kd ALK5 (K232R) were excised from pcDNA1, pCMV5 or pcDNA3-HASL, respectively, and cloned into TJ-neo. Positive clones (evaluated by PCR, restriction analysis and sequencing of the plasmid-cDNA junctions) were cotransfected into 293T producer cells along with retroviral packaging vectors as described previously (Chen et al., 2002) . Retroviral particles released by 293T cells were used to infect PANC-1 cells. Following selection with geneticin, productively infected cells were cultured as genetically homogenous individual clones or as mixtures of clones differing in the proviral insertion site and thus in transgene expression (designated 'pool'). Empty vectortransduced control cells were always used as pools.
RNA isolation and quantitative real-time RT-PCR analysis RNA isolation and first-strand cDNA synthesis were carried out as described (Chen et al., 2002) . Real-time PCR analysis was performed on an I-Cycler (Bio-Rad, Munich, Germany) with SYBR green as fluorochrome and I-Cycler software (BioRad). Data for the genes of interest were independently normalized to at least two functionally unrelated housekeeping genes (b-actin and TATA-box binding protein) according to the DDC t method. The following human oligonucleotide primers were used for PCR amplification (5 0 -3 0 ): TSP-1 forward: CAATCCGGATCAGCTGGACTC, reverse: TGA TGATTAGGGATCTCTACATTCG; VEGF-A forward: CATGAACTTTCTGCTGTCTTGG, reverse: CCTGGTGA GAGATCTGGTTCC; Vimentin forward: TGGCACGTCTT GACCTTGAA, reverse: GGTCATCGTGATGCTGAGAA; E-cadherin forward: TCTTCCCCGCCCTGCCAATC, reverse: GCCTCTCTCGAGTCCCCTAG; Snail forward: CTGCTCC ACAAGCACCAAGAGTC, reverse: CCAGCTGCCCTCCC TCCAC; N-cadherin forward: GTGCCATTAGCCAAGGG AATTC, reverse: CCTGTTCCACTCATAGGAGG; MMP-2 forward: CACCCTGGAGCGAGGGTAC, reverse: CTGATT AGCTGTAGAGCTGAAGGC; TATA-box-binding protein forward: GCTGGCCCATAGTGATCTTT; reverse: CTTCAC ACGCCAAGAAACAG. The primers for PAI-1 and b-actin have been published previously (Chen et al., 2002) .
Transient transfections and reporter gene assays
For reporter gene assays, PANC-1 cells were seeded in 96-well plates and were cotransfected on the next day serum-free with LipofectAMINE Plus (Invitrogen) according to the manufacturer's instructions with ALK5-KR, ALK5-TD or RImL45(TD) cDNAs (in pcDNA3) at an equal molar ratio together with either 3TP-lux or p6SBE (Dai et al., 1998) , pMYC-TA-Luc (Clontech-Takara Bio Europe, Saint Germainen-Laye, France), or mouse Smad7 promoter in pGL3. Each well received the same total amount of DNA and empty vector was added as needed. Following transfection luciferase activities were determined with the Dual Luciferase Assay System (Promega, Heidelberg, Germany) in a GLOMAX apparatus (Promega). In all reporter gene assays, the data were derived from six wells processed in parallel and corrected for transfection efficiency with Renilla luciferase activity. Statistical significance was calculated using the Mann-Whitney U-test.
Immunoblot analysis
Immunoblotting was performed according to standard protocols and as described in a previous publication (Chen et al., 2002) . For immunoblot detection of ALK5 in explanted tumors, the tumor tissue was cryosectioned (20 mm) and the cellular proteins extracted with RIPA buffer. ]-thymidine was essentially done as described previously (Voss et al., 1999) . For determining the proliferative capacity of the ALK5 transductants by cell counting, cells of each clone (50 000) were seeded in 12-well plates (in triplicate) in normal growth medium. Aliquots of the cells were harvested 6 h later (day 0) and then every 2 days and viable (Trypanblue excluding) cells counted in a Neubauer chamber. The EZ4U assay (Biomedica, Vienna, Austria), which utilizes the capability of living 'cells' mitochondria to reduce an uncolored tetrazolium salt into a colored formazan derivative, was performed according to the manufacturer's instructions. Cells were measured 4 h after addition of the reagent and the OD was read at a wavelength of 450 nm.
Flow cytometry analysis
Cells were seeded into cell culture flasks at a concentration of 3-5 Â 10 5 cells/T25 flask. Cells were detached by trypsinization and washed twice in ice-cold PBS containing 5 mM EDTA. After fixation in 100% ethanol (20 min at room temperature (RT) and subsequent centrifugation, cells were resuspended in 500 ml phosphate buffer saline (PBS)-EDTA containing 37.5 mg of RNAse A (Sigma-Aldrich, Taufkirchen, Germany) and incubated for 30 min at RT. Finally, 500 ml of 250 mg/ml propidium iodide (PI, Sigma) were added and PI uptake was determined by fluorescence flow cytometry (FACScalibur; BD Biosciences, Heidelberg, Germany). Cell-cycle analysis was performed using the Cell Quest software.
Orthotopic transplantation of tumor cells into immunodeficient mice
Female SCID-bg (C.B-17/IcrHsd-Prkdc scid Lyst bg ) mice (Harlan Winkelmann, Borchen, Germany) weighing 14-19 g were allowed to become acclimatized for 1 week in a sterile environment where bedding, food and water were autoclaved. Food and water were given ad libitum. Animal experiments and care were in accordance with the guidelines of the institutional authorities. Mice were anesthetized by intraperitoneal (i.p.) injection of a mixture of 5.0 mg/kg Midazolam (Roche, Grenzach-Wehyen, Germany), 0.05 mg/kg Fentanyl (Janssen-Cilag, Neuss; Germany) and 5.0 mg/kg Medetomidin (Pfizer, Karlsruhe, Germany). After completion of the surgical procedure, anesthesia was antagonized by s.c. injection of a mixture of 0.5 mg/kg Flumazenil (Roche), 1.2 mg/kg Naloxon (Curamed, Neuss; Germany) and 2.5 mg/kg Atipamezol (Pfizer). After median laparotomy, the pancreas was carefully exposed and a tumor cell suspension of 1 Â 10 6 cells (in 30 ml Matrigel, BD Biosciences) was cautiously injected into the pancreas. The pancreas was then returned to the peritoneal cavity and the abdominal wall and the skin were closed with 6-0 running absorbable suture (Ethicon, Norderstedt, Germany). The tumor cells were allowed to grow for 28 days. All mice were inspected daily for complications. Following killing of the animals, tumors were resected and their weights and volumes calculated according to the formula of a rotational ellipsoid (V ¼ length Â height Â width Â 0.5236). Resected tumors were bisected and cryo-as well as formalin-fixed for further investigations. Data were analysed using SPSS for Windows (V 11.0, Chicago, IL, USA) and are depicted as means7s.d. Differences in tumor volume between relevant subgroups were analysed with Kruskal-Wallis test and Mann-Whitney U-test and calculated P-values are shown in the graph. A global P-value of less than 0.05 was considered statistically significant.
Routine histology and immunohistochemistry
Following resection, orthotopically growing tumors were split with one-half undergoing formalin fixation followed by embedding in paraplast according to standard procedures, and the other half subjected to rapid freezing in liquid nitrogen. Cryosections (5 mm) were prepared, fixed in acetone for 10 min and stained with ALK5 antibody or normal rabbit serum as control, followed by detection of positive staining with the APAAP method. The proliferative index of the tumor tissue was performed by staining for the nuclear antigen Ki-67 and counting, by two different investigators, of 200 tumor cells in three different 'hot spots' of each cryosection at high-power magnification ( Â 400). The Ki-67 labelling index was calculated as percentage of positive tumor cells. The mean values and standard deviations were derived from three tumorbearing animals of each group with three cryosections analysed per animal. For visualization of intratumoral vascular endothelium, cryosections were stained against CD31 in combination with APAAP detection. Microvessel density was calculated according to Weidner et al. (1991) . Briefly, areas of elevated vascular density were identified and the microvessel entities per optical field (0.19 mm 2 ; Â 400 magnification) were counted in five different areas of each tumor.
Abbreviations ALK5, activin receptor-like kinase 5; EMT, epithelial-tomesenchymal transition; ERK, extracellular signal-regulated kinase; kd, kinase-deficient; MAPK, mitogen-activated protein kinase; MVD, microvessel density; PAI-1, plasminogen activator inhibitor-1; PDAC, pancreatic ductal adenocarcinoma; TGF-b, transforming growth factor-b; TSP-1, thrombospondin-1; VEGF, vascular endothelial growth factor.
